One last thought before I disappear for the day: There is a Cohort 10 coming. Only 2 possibilities--1) enough AEs at current dose to stop escalation phase of the trial and perform the finishing phase of establishing the maximum tolerated dose; 2) not adverse events sufficient to call a dose limiting toxicity reached, and safety for one more escalation to >450 mg/m^2.
IMO, if the next K cohort update reports one more escalation, different from what we have seen with previous cohorts, an escalation above 450 will positively impact the SP because K efficacy will be all but established along with continued safety. Of course this is in combination with the other catalysts around the same time (any day now).
Market Data 
Markets 
AI
